SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
AI Clinical Documentation Market Size to Reach USD 12.78 Billion by 2035 | SNS Insider
The U.S. AI Clinical Documentation Market is projected to grow from USD 0.41 Billion in 2025 to USD 3.96 Billion by 2035, while Europe is expected to reach USD 5.15 Billion from USD 0.42 Billion, supported by rising adoption of ambient AI, generative AI, and automated clinical documentation solutions across healthcare systems.
We Investigated Polymarket’s Deceptive Marketing Campaign. Here’s What We Found.
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.
Auddia Announces LT350 Advancement Toward First AI Datacenter Deployment, Engaging Fresh Consulting to Lead Engineering and Development
Nova Minerals Announces U.S. Redomicile is Complete and Provides a Project Update
Anchorage, Alaska, June 22, 2026 (GLOBE NEWSWIRE) — Nova Minerals Corp (“Nova Minerals” or the “Company”) (NYSE American: NVA | ASX: NVA) is pleased to announce that its redomicile to the United States has been successfully completed and to provide an update on its 2026 field season, with exploration and development activities now well underway.
Nova Minerals Announces U.S. Redomicile is Complete and Provides a Project Update
Anchorage, Alaska, June 22, 2026 (GLOBE NEWSWIRE) — Nova Minerals Corp (“Nova Minerals” or the “Company”) (NYSE American: NVA | ASX: NVA) is pleased to announce that its redomicile to the United States has been successfully completed and to provide an update on its 2026 field season, with exploration and development activities now well underway.
Low-rise new home sales in GTA beat 10-year average for second consecutive month thanks to HST rebate
Toronto, June 22, 2026 (GLOBE NEWSWIRE) — New home buyers in the Greater Toronto Area (GTA) continue to respond positively to the enhanced HST rebate program as low-rise new home sales outperformed its 10-year average for a second consecutive month in May, the Building Industry and Land Development Association (BILD) said today. The HST rebate program remains a historic buying opportunity for those looking to purchase a new home. However, in May the need for clarity on how rebates are administered contributed to some potential buyers delaying purchasing decisions.
Can Tony Dokoupil Weather the War at CBS?
A Hoarder’s Redemption: Bed Bath & Beyond Will Take Your Decades-Old Coupons
Activated Alumina Market Size to Surpass USD 2.26 Billion by 2035 as Global Demand for Water Treatment Solutions Grows | SNS Insider
U.S. Market Projected to Reach USD 0.60 Billion by 2035, While Europe Approaches USD 0.57 Billion Amid Rising Investments in Water Purification and Environmental Compliance
BitDelta Pro selects Iress to power multi-asset trading platform
AI in Chemicals Market Size to Hit $25.89 Billion by 2035 as Smart Manufacturing and AI-Driven Process Optimization Accelerate | Research by SNS Insider
The U.S. AI in Chemicals Market is Expected to Reach $6.98 Billion by 2035, While Europe is Projected to Touch $5.89 Billion, Driven by AI-Powered Production Optimization, Sustainable Chemical Manufacturing, Predictive Analytics, and Rising Investments in Digital Transformation Across the Chemical Industry
FutureCorp Launches Space-Oriented SPAC – Los Angeles Business Journal
FutureCorp Launches Space-Oriented SPAC Los Angeles Business Journal
Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
Oxford, UK, and San Jose, California, 22 June 2026 – Oxford BioTherapeutics (“OBT”), a clinical-stage oncology company specialising in proteomics-driven target discovery for antibody-based therapies enabled by its OGAP®-Verify platform, today announced two new clinical milestones with Boehringer Ingelheim-partnered programmes, BI 3820768 (OB33) and obrixtamig (OBT620).
FORTESCUE AND CMB.TECH SIGN MILESTONE AGREEMENT FOR 12 AMMONIA BULKERS TO ACCELERATE ZERO-EMISSIONS SHIPPING
Antwerp, June 22, 2026 (GLOBE NEWSWIRE) — CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-capable vessels, marking a significant step towards decarbonising global shipping and advancing the adoption of ammonia as a shipping fuel.